Oravax's vaccine technology is highly scalable for manufacturing and is easily transferable for wide scale logistical distribution, as there is no need for freezer storage
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
The new facility will provide an important boost to vaccine capacity in Africa
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Filing marks first protein-based vaccine submitted to MHRA for authorization
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
The company plans to submit the IND application by the end of 2021
Subscribe To Our Newsletter & Stay Updated
